- Home
- BRW vs AGEN Comparison
BRW vs AGEN Comparison
Compare BRW & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.6M | 126.2M |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BRW | AGEN |
|---|---|---|
| Price | $6.47 | $2.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 241.0K | ★ 368.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | ★ N/A | $8.95 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $6.38 | $1.38 |
| 52 Week High | $8.49 | $7.34 |
Technical Indicators
Market Signals| Indicator | BRW | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 44.59 |
| Support Level | N/A | $2.92 |
| Resistance Level | $7.10 | $3.15 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 20.37 | 13.28 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).